S, M., K, H., A, O., T, K., Y, S., A, K., . . . T, S. (2025). Association between sodium-glucose cotransporter-2 inhibitor and adverse events in patients with moderate to severe chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European journal of clinical pharmacology, 81(2), 217. https://doi.org/10.1007/s00228-024-03779-2
Chicago Style (17th ed.) CitationS, Mitsuboshi, Hitoshi K, Ominato A, Kinoshita T, Sugimoto Y, Kajiwara-Morita A, Urata M, Sato K, and Sakamaki T. "Association Between Sodium-glucose Cotransporter-2 Inhibitor and Adverse Events in Patients with Moderate to Severe Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials." European Journal of Clinical Pharmacology 81, no. 2 (2025): 217. https://doi.org/10.1007/s00228-024-03779-2.
MLA (9th ed.) CitationS, Mitsuboshi, et al. "Association Between Sodium-glucose Cotransporter-2 Inhibitor and Adverse Events in Patients with Moderate to Severe Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials." European Journal of Clinical Pharmacology, vol. 81, no. 2, 2025, p. 217, https://doi.org/10.1007/s00228-024-03779-2.
